JP2010504286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504286A5 JP2010504286A5 JP2009527532A JP2009527532A JP2010504286A5 JP 2010504286 A5 JP2010504286 A5 JP 2010504286A5 JP 2009527532 A JP2009527532 A JP 2009527532A JP 2009527532 A JP2009527532 A JP 2009527532A JP 2010504286 A5 JP2010504286 A5 JP 2010504286A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- integer
- alkyl
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 0 Cc(cc1)ccc1-c1c(-c2ccccc2)nc(CNCCC*(O)O)cc1 Chemical compound Cc(cc1)ccc1-c1c(-c2ccccc2)nc(CNCCC*(O)O)cc1 0.000 description 3
- FFSLIJUQAYEYJT-UHFFFAOYSA-N CCc(cc1)ccc1-c1c(-c2ccncc2)nc(CNCCCOPO)cc1 Chemical compound CCc(cc1)ccc1-c1c(-c2ccncc2)nc(CNCCCOPO)cc1 FFSLIJUQAYEYJT-UHFFFAOYSA-N 0.000 description 2
- DSBLSVCSBKZQKP-UHFFFAOYSA-N CCc(cc1)ccc1C1=CC=C(CNCC(CC(O)=O)O)NC1C1=CCCC=C1 Chemical compound CCc(cc1)ccc1C1=CC=C(CNCC(CC(O)=O)O)NC1C1=CCCC=C1 DSBLSVCSBKZQKP-UHFFFAOYSA-N 0.000 description 2
- PKIXUSGPPGWLFE-UHFFFAOYSA-N OP(CCCNCc(cc1)nc(-c2ccccc2)c1-c1ccccc1)(O)=O Chemical compound OP(CCCNCc(cc1)nc(-c2ccccc2)c1-c1ccccc1)(O)=O PKIXUSGPPGWLFE-UHFFFAOYSA-N 0.000 description 2
- WTUCBTBLVOWQGI-UHFFFAOYSA-N CC1C(c2ccccc2)C(c2ccc(C)cc2)=CC=C(COCCCP(O)(O)=O)CC1 Chemical compound CC1C(c2ccccc2)C(c2ccc(C)cc2)=CC=C(COCCCP(O)(O)=O)CC1 WTUCBTBLVOWQGI-UHFFFAOYSA-N 0.000 description 1
- QZSGATSDHMXWLY-UHFFFAOYSA-N CCC(C=C1)=CCC1C1=CCC(CNCCCP(O)O)N=C1c1ccncc1 Chemical compound CCC(C=C1)=CCC1C1=CCC(CNCCCP(O)O)N=C1c1ccncc1 QZSGATSDHMXWLY-UHFFFAOYSA-N 0.000 description 1
- YLBFYGJECVHLDH-UHFFFAOYSA-N CCC(C=C1)=CCC1C1=CCC(COCCCP(O)O)N=C1c1ccccc1 Chemical compound CCC(C=C1)=CCC1C1=CCC(COCCCP(O)O)N=C1c1ccccc1 YLBFYGJECVHLDH-UHFFFAOYSA-N 0.000 description 1
- AIBDVDJSCMNDDG-UHFFFAOYSA-N CCCCOCC(NC1C2=CCCC=C2)=CC=C1c1ccc(C)cc1 Chemical compound CCCCOCC(NC1C2=CCCC=C2)=CC=C1c1ccc(C)cc1 AIBDVDJSCMNDDG-UHFFFAOYSA-N 0.000 description 1
- JEWGRYIRSLGDRP-UHFFFAOYSA-N CCCc(cc1)ccc1C1=CCC(CNCCCP(O)(O)=O)N=C1c1ccccc1 Chemical compound CCCc(cc1)ccc1C1=CCC(CNCCCP(O)(O)=O)N=C1c1ccccc1 JEWGRYIRSLGDRP-UHFFFAOYSA-N 0.000 description 1
- DLTIFALHRSYDKJ-UHFFFAOYSA-N CCc(cc1)ccc1-c1c(C2=CCCC=C2)nc(CNCCP(O)(O)=O)cc1 Chemical compound CCc(cc1)ccc1-c1c(C2=CCCC=C2)nc(CNCCP(O)(O)=O)cc1 DLTIFALHRSYDKJ-UHFFFAOYSA-N 0.000 description 1
- BRPCZYXCBFUTPT-UHFFFAOYSA-N CCc(cc1)ccc1C1=CC=C(CNCCP(O)(O)=O)CC1C1=CCCC=C1 Chemical compound CCc(cc1)ccc1C1=CC=C(CNCCP(O)(O)=O)CC1C1=CCCC=C1 BRPCZYXCBFUTPT-UHFFFAOYSA-N 0.000 description 1
- ONMXHBAWHRLKHR-UHFFFAOYSA-N CCc1ccc(C2C(C3=CCCC=C3)[N-]C(CNCCCP(C(O)O)=O)=CC2)cc1 Chemical compound CCc1ccc(C2C(C3=CCCC=C3)[N-]C(CNCCCP(C(O)O)=O)=CC2)cc1 ONMXHBAWHRLKHR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82480706P | 2006-09-07 | 2006-09-07 | |
| PCT/US2007/077588 WO2008030843A1 (en) | 2006-09-07 | 2007-09-05 | Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010504286A JP2010504286A (ja) | 2010-02-12 |
| JP2010504286A5 true JP2010504286A5 (cg-RX-API-DMAC7.html) | 2010-10-21 |
Family
ID=38961939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527532A Pending JP2010504286A (ja) | 2006-09-07 | 2007-09-05 | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体アゴニスト及び／又はアンタゴニスト生物活性を有するヘテロ芳香族化合物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2066633A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010504286A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007292347A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0716815A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2662852A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008030843A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005014271A1 (de) * | 2005-03-24 | 2006-09-28 | Rhein Chemie Rheinau Gmbh | Mikrogele in Kombination mit funktionalen Additiven |
| WO2008141013A1 (en) * | 2007-05-08 | 2008-11-20 | Allergan, Inc. | S1p3 receptor inhibitors for treating pain |
| WO2010011316A1 (en) | 2008-07-23 | 2010-01-28 | Arena Pharmaceuticals, Inc. | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS |
| KR101800595B1 (ko) | 2008-08-27 | 2017-11-22 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한, ｓ1ｐ1 수용체 효능제로서의 치환된 트리시클릭 산 유도체 |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| WO2011066179A1 (en) * | 2009-11-24 | 2011-06-03 | Allergan, Inc. | Novel compounds as receptor modulators with therapeutic utility |
| US8741875B2 (en) | 2009-11-24 | 2014-06-03 | Allergan, Inc. | Compounds as receptor modulators with therapeutic utility |
| WO2011094008A1 (en) | 2010-01-27 | 2011-08-04 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| US8835470B2 (en) | 2010-04-23 | 2014-09-16 | Bristol-Myers Squibb Company | Mandelamide heterocyclic compounds |
| US8513220B2 (en) | 2010-05-14 | 2013-08-20 | Allergan, Inc. | Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity |
| US20110281822A1 (en) | 2010-05-14 | 2011-11-17 | Allergan, Inc. | Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity |
| WO2012040532A1 (en) | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| EA032028B1 (ru) | 2013-12-11 | 2019-03-29 | Айронвуд Фармасьютикалз, Инк. | СТИМУЛЯТОРЫ рГЦ |
| EP3242666B9 (en) | 2015-01-06 | 2024-12-25 | Arena Pharmaceuticals, Inc. | Compound for use in treating conditions related to the s1p1 receptor |
| IL285890B (en) | 2015-06-22 | 2022-07-01 | Arena Pharm Inc | Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid |
| MA47503A (fr) | 2017-02-16 | 2021-04-21 | Arena Pharm Inc | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales |
| MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
| KR102859841B1 (ko) | 2018-06-06 | 2025-09-12 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 병태의 치료 방법 |
| WO2020051378A1 (en) | 2018-09-06 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2665159B1 (fr) * | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| WO1992002513A1 (en) * | 1990-08-06 | 1992-02-20 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| CA2547198A1 (en) * | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
-
2007
- 2007-09-05 BR BRPI0716815-2A2A patent/BRPI0716815A2/pt not_active IP Right Cessation
- 2007-09-05 AU AU2007292347A patent/AU2007292347A1/en not_active Abandoned
- 2007-09-05 EP EP07841853A patent/EP2066633A1/en not_active Withdrawn
- 2007-09-05 JP JP2009527532A patent/JP2010504286A/ja active Pending
- 2007-09-05 WO PCT/US2007/077588 patent/WO2008030843A1/en not_active Ceased
- 2007-09-05 CA CA002662852A patent/CA2662852A1/en not_active Abandoned